Invention Grant
- Patent Title: Bispecific antibody binding BCMA and CD3
-
Application No.: US17290401Application Date: 2019-09-26
-
Publication No.: US12030939B2Publication Date: 2024-07-09
- Inventor: Qiang Li , Shixiang Jia , Lili Zhao , Guimin Zhang , Zhong Liu , Xinlu Ma , Yuan Yan , Zhenyu Li , Xingxia Hu , Yuhua Zhang , Bin Li
- Applicant: SHANDONG NEW TIME PHARMACEUTICAL CO., LTD.
- Applicant Address: CN Shandong
- Assignee: Shandong New Time Pharmaceutical Co., Ltd.
- Current Assignee: Shandong New Time Pharmaceutical Co., Ltd.
- Current Assignee Address: CN Shandong
- Agency: McCarter & English, LLP
- Agent Maria Laccotripe Zacharakis; Yu Lu
- Priority: CN 1811294887.4 2018.11.01
- International Application: PCT/CN2019/108057 2019.09.26
- International Announcement: WO2020/088164A 2020.05.07
- Date entered country: 2021-04-30
- Main IPC: C07K16/30
- IPC: C07K16/30 ; A61K39/395 ; A61K45/06 ; A61P35/00 ; C07K16/28 ; C07K16/32 ; C07K16/46 ; C12N15/62 ; C12N15/85 ; A61K39/00

Abstract:
The invention provided herein relates to methods and uses of a bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests.
Public/Granted literature
- US20230416385A1 BISPECIFIC ANTIBODY AND USE THEREOF Public/Granted day:2023-12-28
Information query